formulation according to any one of claims 16 to 17 for use in the treatment of inflammatory or autoimmune diseases selected from myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, and thrombotic thrombocytopenic purpura, Idiopathic thrombocytopenic purpura (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP) and combinations thereof.

21. Use of a pharmaceutical composition according to any one of claims 1 to 12, use of the freeze-dried formulation according to any one of claims 13 to 15 or use of the liquid pharmaceutical formulation according to any one of claims 16 to 17 in the manufacture of a medicament for treating an inflammatory or autoimmune disease in a mammalian subject, wherein the inflammatory or autoimmune disease is selected from myasthenia gravis, Pemphigus vulgaris, Neuromyelitis optica, Guillain-Barré syndrome, lupus, and thrombotic thrombocytopenic purpura, Idiopathic thrombocytopenic purpura (ITP), Chronic inflammatory demyelinating polyneuropathy (CIDP) and combinations thereof.
22. A method for producing a pharmaceutical composition comprising an anti-FcRn antibody, wherein the method comprises the steps of:
    (i) preparing a composition comprising an anti-FcRn antibody; and
    (ii) adding 1% to 20% w/v sucrose.
23. The method according to claim 22 wherein the pharmaceutical composition resulting from step (ii) is a pharmaceutical composition according to any one of claims 1 to 12.
24. The method according to claim 22 or claim 23, wherein the method further comprises the step of freeze-drying the pharmaceutical composition resulting from step (ii).
25. The pharmaceutical composition obtained by the method according to claim 24.
26. A method for reconstituting a pharmaceutical composition according to any one of claims 13, 14, 15, 24 or 25 by adding a solvent, wherein the solvent is preferably water.
27. A liquid pharmaceutical formulation obtained by the method according to claim 26.